ARQ 621, a novel potent and selective inhibitor of Eg5: Preclinical data and early results from a clinical phase 1 study

被引：5
|
作者：
Rosen, Lee
Chen, Lin-Chi
Iyengar, Tara
Goldman, Jonathan
Lahr, Sandra
Chen, Chang-Rung
France, Dennis S.
Chan, Thomas C. K.
Schwartz, Brian
Abbadessa, Giovanni
Von Hoff, Daniel D.
机构：
来源：
CANCER RESEARCH | 2010年 / 70卷
关键词：
D O I：
10.1158/1538-7445.AM10-2750
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2750
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Selective Histone Deacetylase Inhibitor ACY-241 Plus Nivolumab for Refractory Advanced NSCLC: Results From a Phase 1b Study
    Awad, M.
    Le Bruchec, Y.
    Markelewicz, R.
    Chen, P.
    Fandi, A.
    Spira, A.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1804 - S1804
  • [42] Efficacy of pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in Richter transformation: Results from the phase 1/2 BRUIN study
    Rhodes, Joanna
    Lewis, David
    Ghia, Paolo
    Shah, Nirav N.
    Coombs, Catherine C.
    Cheah, Chan Y.
    Woyach, Jennifer
    Lamanna, Nicole
    Hoffmann, Marc S.
    Ma, Shuo
    Eyre, Toby A.
    Munir, Talha
    Patel, Manish R.
    Alencar, Alvaro J.
    Tam, Constantine S.
    Seymour, John F.
    Jurczak, Wojciech
    Lech-Maranda, Ewa
    Roeker, Lindsey E.
    Thompson, Philip A.
    Abada, Paolo B.
    Wang, Chunxiao
    Nair, Binoj
    Liu, Hui
    Tsai, Donald E.
    Mato, Anthony R.
    Wierda, William G.
    CANCER RESEARCH, 2023, 83 (08)
  • [43] Efficacy and safety of LY3537982, a potent and highly selective KRAS G12C inhibitor in KRAS G12C-mutant GI cancers: Results from a phase 1 study
    Kuboki, Yasutoshi
    Murciano-Goroff, Yonina R.
    Yaeger, Rona
    Cassier, Philippe Alexandre
    Heist, Rebecca Suk
    Fujiwara, Yutaka
    Deming, Dustin A.
    Ammakkanavar, Natraj
    Patnaik, Amita
    Shimizu, Toshio
    Call, Justin
    Han, Sae-Won
    Fink, Aaron Alan
    Chen, Aaron
    Willard, Melinda D.
    Balar, Arjun Vasant
    Koyama, Takafumi
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 94 - 94
  • [44] Updated results from a Phase I study of AV-951 (KRN951), a potent and selective VEGFR-1,-2 and-3 tyrosine kinase inhibitor, in patients with advanced solid tumors
    Eskens, Ferry A. L. M.
    de Jonge, Maja J. A.
    Esteves, Brooke
    Cotreau, Monette
    Bhargava, Pankaj
    Ryan, John
    van Doorn, Leny
    Isoe, Toshiyuki
    Hayashi, Kunihiko
    Ekman, Lena
    Burger, Herman
    Verweij, Jaap
    CANCER RESEARCH, 2008, 68 (09)
  • [45] Preliminary Data From the Phase 1/2 Study of TP-3654, an Investigational Selective PIM1 Kinase Inhibitor, Showed Cytokine Reduction and Clinical Responses in Relapsed/Refractory Myelofibrosis (MF)
    El Chaer, Firas
    Rein, Lindsay
    Shimoda, Kazuya
    Yuda, Junichiro
    Haque, Tamanna
    McCloskey, James
    Takami, Akiyoshi
    Fukaya, Masafumi
    Shirane, Shuichi
    Kabir, Sujan
    Mei, Jian
    Seki, Masataka
    Li, Zhonggai
    Wade, Mark
    Lebedinsky, Claudia
    Rampal, Raajit K.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S395 - S396
  • [46] OSI-906: A novel, potent, and selective first-in-class small molecule insulin-like growth factor 1 receptor (IGF-1R) inhibitor in phase I clinical trials
    Volk, Brian
    Buck, Elizabeth
    Coate, Heather
    Cooke, Andrew
    Dong, Hanging
    Eyzaguirre, Alexandra
    Feng, Lixin
    Foreman, Ken
    Rosenfeld-Franklin, Maryland
    Kleinberg, Andrew
    Landfair, Darla
    Mak, Gilda
    Nigro, Anthony
    O'Connor, Matthew
    Pirritt, Caroline
    Silva, Stacia
    Siu, Kam
    Steinig, Arno
    Stolz, Kate
    Tavares-Greco, Paula
    Turton, Roy
    Werner, Doug
    Yao, Yan
    Arnold, Lee
    Gibson, Neil W.
    Pachter, Jon A.
    Wild, Robert
    Ji, Qun-Sheng
    Mulvihill, Mark J.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2009, 238
  • [47] Results from a Phase 1/2 Study of INCB050465, a Highly Selective and Highly Potent PI3Kδ Inhibitor, in Patients with Relapsed or Refractory B-Cell Malignancies (CITADEL-101)
    Forero-Torres, Andres
    Ramchandren, Rod
    Yacoub, Abdulraheem
    Wertheim, Michael S.
    Edenfield, William J.
    Caimi, Paolo
    Gutierrez, Martin
    Akard, Luke
    Escobar, Carolina
    Call, Justin
    Persky, Daniel
    Iyer, Swami P.
    DeMarini, Douglas J.
    Zhou, Li
    Yeleswaram, Swamy
    Phillips, Tycel J.
    BLOOD, 2017, 130
  • [48] FILGOTINIB, A SELECTIVE JAK1 INHIBITOR, INDUCES CLINICAL REMISSION AND A REDUCTION IN PSTAT3 LEVELS IN PATIENTS WITH ACTIVE CROHN'S DISEASE: RESULTS FROM THE PHASE II FITZROY STUDY
    Keshav, S.
    Goh, J.
    Hart, A.
    Levison, S.
    McLaughlin, S.
    Van der Aa, A.
    Galien, R.
    Pan, Y.
    Meuleners, L.
    Jamoul, C.
    Tasset, C.
    Harrison, P.
    Vermeire, S.
    GUT, 2017, 66 : A25 - A25
  • [49] Preclinical and clinical pharmacodynamic characterization of BBI-355, a novel, orally bioavailable, and selective CHK1 inhibitor being evaluated in the first-in-human Phase 1/2 POTENTIATE clinical trial of patients with cancer harboring oncogene amplifications
    Liao, Debbie
    Hansen, Ryan
    Chowdhry, Sudhir
    Holmes, Evan
    Wiese, Julie
    Steffy, Auzon
    Pferdekamper, AnneMarie
    Tse, Edison
    Garcia, Salvador
    Reynolds, Rebecca
    Weymer, Sara
    Wagner, Klaus
    Hassig, Chris
    Kasibhatla, Shailaja
    CANCER RESEARCH, 2024, 84 (06)
  • [50] Primary Analysis Results from an Open-Label Phase II Study of INCB039110, a Selective JAK1 Inhibitor, in Patients with Myelofibrosis
    Mascarenhas, John O.
    Talpaz, Moshe
    Gupta, Vikas
    Foltz, Lynda M.
    Savona, Michael R.
    Paquette, Ron
    Turner, Robert
    Coughlin, Paul
    Winton, Elliott
    Hunter, Deborah
    Assad, Albert
    Clark, Jason
    O'Neill, Peter
    Hoffman, Ronald
    Verstovsek, Srdan
    BLOOD, 2014, 124 (21)
12345